Important note: Information in this article was accurate in January 2009. The state of the art may have changed since the publication date.
Dosing of lopinavir/ritonavir in the CHIPS cohort
HIV Treat Bull - 2009 Jan-Feb;10(1/2): 09
Polly Clayden, HIV i-Base
Sarah Walker from the Medical Research Council presented data from the UK/Irish Collaborative HIV Paediatric Study (CHIPS) cohort looking at paediatric dosing of lopinavir/ritonavir (LPV/r).[1]
Dr Walker explained that the licensed LPV/r paediatric daily dose is 460 mg/m2 without, and 600 mg/m2 with concomitant NNRTI therapy. The 460 mg/m2 dose without NNRTIs was chosen in preference to 600 mg/m2 in a post-hoc drug-interaction analysis[2]. Following the completion of the phase II trial, this post-hoc analysis revealed a significant interaction between NNRTI and LPV/r, leading to the lower dose being licensed for use without NNRTI. The phase II trial showed very good viral load data overall, with 79% of children <400 copies/mL at 48 weeks, but this was based on the higher 600 mg/m2 dose. Because of this uncertainty some paediatricians prefer to prescribe the higher dose of LPV/r irrespective of concomitant NNRTI therapy.In the CHIPS study the investigators evaluated the LPV/r doses prescribed without NNRTIs in the cohort from 2000– 2007.
They looked at predictors of current dose, including sex, VL and CD4, age, CDC stage, height/weight-for-age, calendar year, formulation, frequency and previous PI use, using mixed models allowing child and hospital effects.
They also evaluated the impact of the LPV/r dose on viral load suppression 6 months after starting it using logistic models and over longer follow up using binomial mixed models.
Dr Walker reported, 311/1,336 (25%) children in the cohort had received LPV/r without an NNRTI; for a total of 654 child- years. Of these children, 238 (77%) were still on LPV/r when they were seen last.
The median age of the children at initiation of LPV/r was 9 (IQR 5–12) years. The investigators recorded 684 doses in 299/311 children of which 52% were syrup, 38% capsules and 10% tablets. 662 (97%) doses were taken twice daily.
Overall the dose/m2 could be estimated 2,748 times in 278 children (the remaining children did not have height/weight recorded). They found few (7%) doses were >10% below the 460 mg/m2 target, and few (9%) >10% above the 600 mg/m2 target, with the majority >410–<530 mg/m2 (46%) or >530–<660 mg/m2 (39%).
In a multivariate analysis, the investigators found doses were: 17 mg/m2 [95%CI 0–34], higher in children who had prior CDC C event, (p=0.05; 2 mg/m2 [0–3] higher for every log10 higher VL, (p=0.02; 48 mg/m2 [38–58] higher with capsules/tablets vs syrups, p<0.001; 22 mg/m2 [4–40] higher with twice- vs once-daily dosing, (p=0.02; 19 mg/m2 [15–24], (p=0.001, and 10 mg/m2 [6–14], p<0.001 higher for every one unit lower current weight- and height-for-age, respectively; and 9 mg/m2 [5–14] higher for every year younger over 10, p<0.05.
Dr Walker noted that the mean dose for a 10 year old, without prior CDC event, average weight and age for height receiving capsules or tablets was 546mg/m2. She also noted that dosing varied greatly by centre with some using higher and some lower doses.
The investigators found no evidence that the initial LPV/r dose was associated with significantly improved viral load suppression at 6 months and reported: <400 copies/mL, AOR=1.06 per 50 mg/m2 (95%CI 0.87-1.28), (p=0.58; <50 copies/mL, AOR=0.81 per 50mg/m2 (95%CI 0.65-1.01), (p=0.06.
The investigators concluded: “Doses were higher with capsules/tablets, likely reflecting over- rather than under-dosing when solid formulations cannot achieve exact doses. However, we found no clear evidence that higher doses improved VL suppression.”
Dr Walker added: “Opinion seems to be split as to the most appropriate LPV/r dose in children.”
References
2009-02-10
IB2009-01-09
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.